<DOC>
	<DOCNO>NCT00665834</DOCNO>
	<brief_summary>This 3-month , randomize , parallel-group study 2 period , compare efficacy safety rosuvastatin 20 mg versus atorvastatin 80 mg patient acute coronary syndrome ( ACS ) .</brief_summary>
	<brief_title>Comparison Rosuvastatin Atorvastatin Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>Patients ACS ( acute coronary syndrome ) constitute high-risk population unstable coronary disease ( CHD ) differs stable CHD primarily short term prognosis ( prediction outcome ) . The 1-year rate death non-fatal MI ( myocardial infarction heart attack ) 13 % patient ACS recent control study ( FRISC II 1999 ) , compare less 2 % patient stable CHD ( SAPAT 1992 ) . Thus , despite substantial progress treatment ACS antiplatelet anti-thrombotic medication ( blood thinner ) , additional therapy need reduce additional risk associate unstable CHD . Current guideline ( NCEP 2001 ) recommend patient admit major coronary event ( MI ACS ) consider treatment statin discharge hospital . Cited advantage approach patient motivation start therapy time prevention `` treatment gap '' due inconsistent outpatient follow-up . A previously randomize control study statin therapy ACS patient ( MIRACL study ) , show aggressive cholesterol lower atorvastatin 80 mg 24 96 hour hospital admission patient ACS result reduced incidence recurrent CHD event 16 week . However , study exclude patient underwent revascularization ( PCI ) . Thus study enrol subset ACS population . There also emerge data clinical study support anti-inflammatory action statin . One recent randomize control study demonstrate statin decrease level CRP , consider marker intra-arterial inflammation predictor recurrent adverse cardiovascular event . The relative level various lipid measurement , LDL-C , triglycerides HDL-C probably influence inflammatory thrombotic ( blood clot ) property , exact relationship clear . The anti-inflammatory antithrombotic property different statin likely related impact lipid profile different pleiotropic property ( produce one genetic effect ) . The present study design compare effect rosuvastatin 20 mg versus atorvastatin 80 mg start maximum 6 day ACS lipid profile ( blood cholesterol ) . Additionally , hypothesis beneficial effect inflammatory marker compare statin start later test . c ) Summary study design : This 3-month , randomize , parallel-group study 2 period , compare efficacy safety rosuvastatin 20 mg versus atorvastatin 80 mg patient acute coronary syndrome ( ACS ) . - The study comprise 1st double blind , placebo control , period start admission patient ACS ( clinical symptom le 24 hour ) hospital discharge ( maximum timeline 6 day ) . - The 2nd double blind , double dummy , period start Day 0 ( i.e . hospital discharge maximum 6 day admission ) last 3 month . After validation eligibility criterion ( include 1st local assessment CK , creatinine , ALT ECG ) plan PCI 24 hour 4 day admission , patient randomize 3 group : 1. early start rosuvastatin 20 mg admission end study ( group 1 - early rosuvastatin 20 mg ) , 2. placebo admission Day O ( i.e . hospital discharge maximum 6 day ) follow rosuvastatin 20 mg end study ( group 2 - late rosuvastatin 20 mg ) , 3. placebo admission Day O ( i.e . hospital discharge maximum 6 day ) follow atorvastatin 80 mg end study ( group 3 - atorvastatin 80 mg ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Men woman 18 75 year old Patients diagnose non ST elevation acute coronary syndrome ( NSTEACS ) Patients onset clinical symptom le 24 hour prior admission PCI plan anticipate . Patients STEMI ( ST elevation myocardial infarctionheart attack ) primary PCI plan within 24 hour admission include . Patients allow take cholesterollowering medication 1 month prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>